Fig.12 Comparison of treatment drugs sensitivity between high- and low-risk groups A: IC50 of Nilotinib in high- and low-risk groups B: IC50 of Gefitinib in high- and low-risk groups C: IC50 of Erlotinib in high- and low-risk groups D: IC50 of Axitinib in high- and low-risk groups E: IC50 of Tipifarnib high- and low-risk groups groups F: IC50 of mitomycin C in high- and low-risk groups
Other figure/table from this article